Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches

Area of Science:

• Oncology
• Pharmacometrics
• Molecular Biology

Background:

• Circulating tumor DNA (ctDNA) shows promise as a biomarker in cancer treatment.
• Understanding ctDNA dynamics alongside clinical response is crucial for drug development.
• Model-informed drug development (MIDD) can leverage ctDNA data.

Purpose of the Study:

• To explore relationships between ctDNA changes, clinical response, and tumor size dynamics.
• To identify opportunities for pharmacometrics in optimizing ctDNA sampling strategies.
• To highlight challenges and the need for mechanistic modeling of ctDNA biology.

Main Methods:

• Exploratory analysis of ctDNA levels, clinical response, and tumor size.
• Analysis of data from cancer patients treated with checkpoint inhibitors and targeted therapies.
• Focus on pharmacometrics and mechanistic modeling approaches.

Main Results:

• Treatment-induced ctDNA changes correlate with clinical response and tumor size dynamics.
• Pharmacometrics offers potential for optimizing sampling strategies for ctDNA.
• Data variability and complexity present challenges for modeling.

Conclusions:

• Mechanistic modeling of ctDNA shedding, release, and clearance is essential.
• Integrating ctDNA dynamics with tumor size and treatment effects requires robust models.
• Further research into ctDNA biology will enhance model-informed drug development.